Last reviewed · How we verify

NCT05995093

The Proactive Diagnostic Value of Hemostatic Biomarkers in Disseminated Intravascular Coagulation

Status unknown Last updated 24 October 2023
What this trial tests

trial testing no intervention in Disseminated Intravascular Coagulation in 462 participants. Status unknown.

Timeline
1 December 2022
Primary endpoint
31 December 2023
30 June 2024

Quick facts

Lead sponsorQilu Hospital of Shandong University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment462
Start date1 December 2022
Primary completion31 December 2023
Estimated completion30 June 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Qilu Hospital of Shandong University

Who can join

Adults 18 to 94, any sex, with Disseminated Intravascular Coagulation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The project was undertaking by Qilu Hospital of Shandong University, aiming to evaluate diagnostic performance of hemostatic biomarkers in disseminated intravascular coagulation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Disseminated Intravascular Coagulation

Currently open trials in the same condition.

Other Qilu Hospital of Shandong University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05995093.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing